According to a report from businesswire on January 24th, Organigram Holdings Inc. (stock code: OGI, TSX: OGI), a holder of a marijuana production license, announced the completion of the initial delivery of a previously announced 125 million Canadian dollars (approximately 92.47 million US dollars) strategic equity investment ("investment") by BT DE Investments Inc., a wholly-owned subsidiary of British American Tobacco plc ("BAT").
According to the initial delivery, investors purchased 12,893,175 common shares of the company at a price of CAD 3.2203 per share, generating a total fundraising of CAD 41,519,891. The remaining 25,786,350 subscription shares will be delivered at a per share price around August 30, 2024, and February 28, 2025.
Paolo De Luca, Chief Strategy Officer at Organigram, stated, "With shareholders formally approving this transformative transaction and the completion of initial financing, we look forward to achieving our goals of geographic and technological growth, as well as product expansion." He added, "Since announcing this deal on November 6, 2023, we have seen tremendous interest from cannabis companies seeking strategic partnership opportunities and growth capital. With its strong balance sheet and focused Jupiter capital pool, Organigram is uniquely positioned to tackle the ever-emerging opportunities."
According to reports, the majority of the investment will be used by Organigram to create a strategic investment pool called Jupiter. Jupiter will focus on investing in emerging cannabis opportunities, allowing Organigram to apply its industry-leading capabilities to new markets. Management has identified geographic expansion as a strategic priority, and this opportunity enables the company to establish a global presence amidst significant ongoing growth in the legalized recreational cannabis market. Organigram has stated its commitment to maintaining the highest levels of regulatory and product oversight, and will continue to closely monitor the cannabis regulatory landscape.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
